Key Roles of EMT for Adaptive Resistance to MEK Inhibitor in KRAS Mutant Lung Cancer

Overview

Journal Small GTPases

Specialties Biochemistry
Cell Biology

Date 2016 Jul 9

PMID 27392325

Citations 10

Authors

Hidenori Kitai

Hiromichi Ebi

Affiliations

Soon will be listed here.

Abstract

KRAS is frequently mutated in a variety of cancers including lung cancer. Whereas the mitogen-activated protein kinase (MAPK) is a well-known effector pathway of KRAS, blocking this pathway with MEK inhibitors is relatively ineffective. One major contributor to limited efficacy is attributed to the reactivation of MAPK signal following MEK inhibition by multiple feedback mechanisms. In a recent study, we have identified that epithelial-to-mesenchymal transition defines feedback activation of receptor tyrosine kinase signaling following MEK inhibition in KRAS mutant lung cancer. In epithelial-like cells, this feedback was mediated by ERBB3. In contrast, in mesenchymal-like cells, the feedback was attributed to the fibroblast growth factor receptor 1 (FGFR1) pathway. FGFR1 was dominantly expressed in mesenchymal-like cells: suppression of SPRY proteins by MEK inhibition relieved negative feedback control of basal FGFR-FRS2 function, resulting in reactivation of MAPK signaling via FGFR1. Therapeutically, the combination of MEK inhibitor trametinib with an FGFR inhibitor induced tumor regressions in tumor xenografts derived from mesenchymal-like KRAS mutant cancer cell lines as well as a patient derived xenograft model with a representative mesenchymal phenotype. Collectively, feedback activation of MAPK by FGFR1 signaling mitigates the effect of MEK inhibitor in mesenchymal-like KRAS mutant lung tumors, and combinations of clinically available FGFR1 inhibitors and MAPK inhibitors constitute a therapeutic approach to treat these cancers effectively.

Citing Articles

Chemically modified MIR143-3p exhibited anti-cancer effects by impairing the KRAS network in colorectal cancer cells.

Sugito N, Heishima K, Akao Y Mol Ther Nucleic Acids. 2022; 30:49-61.

PMID: 36189421 PMC: 9507988. DOI: 10.1016/j.omtn.2022.09.001.

Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors.

Indini A, Rijavec E, Ghidini M, Cortellini A, Grossi F Pharmaceutics. 2021; 13(5).

PMID: 34064352 PMC: 8147792. DOI: 10.3390/pharmaceutics13050653.

Deep generative neural network for accurate drug response imputation.

Jia P, Hu R, Pei G, Dai Y, Wang Y, Zhao Z Nat Commun. 2021; 12(1):1740.

PMID: 33741950 PMC: 7979803. DOI: 10.1038/s41467-021-21997-5.

FGFR-TKI resistance in cancer: current status and perspectives.

Yue S, Li Y, Chen X, Wang J, Li M, Chen Y J Hematol Oncol. 2021; 14(1):23.

PMID: 33568192 PMC: 7876795. DOI: 10.1186/s13045-021-01040-2.

Targeting -Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on Mutations.

Burns T, Borghaei H, Ramalingam S, Mok T, Peters S J Clin Oncol. 2020; 38(35):4208-4218.

PMID: 33104438 PMC: 7723684. DOI: 10.1200/JCO.20.00744.

References

Fischer K, Durrans A, Lee S, Sheng J, Li F, Wong S . Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015; 527(7579):472-6. PMC: 4662610. DOI: 10.1038/nature15748. View

Cox A, Fesik S, Kimmelman A, Luo J, Der C . Drugging the undruggable RAS: Mission possible?. Nat Rev Drug Discov. 2014; 13(11):828-51. PMC: 4355017. DOI: 10.1038/nrd4389. View

Duncan J, Whittle M, Nakamura K, Abell A, Midland A, Zawistowski J . Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell. 2012; 149(2):307-21. PMC: 3328787. DOI: 10.1016/j.cell.2012.02.053. View

Zheng X, Carstens J, Kim J, Scheible M, Kaye J, Sugimoto H . Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015; 527(7579):525-530. PMC: 4849281. DOI: 10.1038/nature16064. View

Singh A, Sweeney M, Yu M, Burger A, Greninger P, Benes C . TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell. 2012; 148(4):639-50. PMC: 3291475. DOI: 10.1016/j.cell.2011.12.033. View

Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N . A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell. 2009; 15(6):489-500. PMC: 2743093. DOI: 10.1016/j.ccr.2009.03.022. View

Kalluri R, Weinberg R . The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6):1420-8. PMC: 2689101. DOI: 10.1172/JCI39104. View

Caunt C, Sale M, Smith P, Cook S . MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer. 2015; 15(10):577-92. DOI: 10.1038/nrc4000. View

Hayes T, Neel N, Hu C, Gautam P, Chenard M, Long B . Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Cancer Cell. 2016; 29(1):75-89. PMC: 4816652. DOI: 10.1016/j.ccell.2015.11.011. View

10.

Lito P, Solomon M, Li L, Hansen R, Rosen N . Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science. 2016; 351(6273):604-8. PMC: 4955282. DOI: 10.1126/science.aad6204. View

11.

Turke A, Song Y, Costa C, Cook R, Arteaga C, Asara J . MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 2012; 72(13):3228-37. PMC: 3515079. DOI: 10.1158/0008-5472.CAN-11-3747. View

12.

Kitai H, Ebi H, Tomida S, Floros K, Kotani H, Adachi Y . Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer. Cancer Discov. 2016; 6(7):754-69. PMC: 4957999. DOI: 10.1158/2159-8290.CD-15-1377. View

13.

Sun C, Hobor S, Bertotti A, Zecchin D, Huang S, Galimi F . Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Rep. 2014; 7(1):86-93. DOI: 10.1016/j.celrep.2014.02.045. View

14.

Rebecca V, Alicea G, Paraiso K, Lawrence H, Gibney G, Smalley K . Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma. Pigment Cell Melanoma Res. 2014; 27(6):1154-8. PMC: 4211982. DOI: 10.1111/pcmr.12303. View

15.

Ham J, Costa C, Sano R, Lochmann T, Sennott E, Patel N . Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination. Cancer Cell. 2016; 29(2):159-72. PMC: 4749542. DOI: 10.1016/j.ccell.2016.01.002. View

16.

Stephen A, Esposito D, Bagni R, McCormick F . Dragging ras back in the ring. Cancer Cell. 2014; 25(3):272-81. DOI: 10.1016/j.ccr.2014.02.017. View

17.

Young A, Lou D, McCormick F . Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov. 2012; 3(1):112-23. DOI: 10.1158/2159-8290.CD-12-0231. View

18.

Zeisberg M, Neilson E . Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009; 119(6):1429-37. PMC: 2689132. DOI: 10.1172/JCI36183. View

19.

Athuluri-Divakar S, Vasquez-Del Carpio R, Dutta K, Baker S, Cosenza S, Basu I . A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling. Cell. 2016; 165(3):643-55. PMC: 5006944. DOI: 10.1016/j.cell.2016.03.045. View

20.

Morris E, Jha S, Restaino C, Dayananth P, Zhu H, Cooper A . Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013; 3(7):742-50. DOI: 10.1158/2159-8290.CD-13-0070. View